Tempus AI (NASDAQ:TEM) Releases Earnings Results, Beats Expectations By $0.01 EPS

Tempus AI (NASDAQ:TEM) posted its earnings results on Tuesday. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01, FiscalAI reports. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The firm had revenue of $367.21 million for the quarter, compared to analyst estimates of $362.55 million.

Tempus AI Price Performance

Shares of TEM stock traded up $0.66 on Tuesday, reaching $57.95. 4,981,486 shares of the company were exchanged, compared to its average volume of 5,650,480. The company has a market cap of $10.31 billion, a price-to-earnings ratio of -48.70 and a beta of 5.22. The business has a 50-day moving average price of $62.13 and a 200 day moving average price of $73.61. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28. Tempus AI has a 1 year low of $36.22 and a 1 year high of $104.32.

Insider Transactions at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 166,250 shares of the firm’s stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $65.56, for a total value of $10,899,350.00. Following the transaction, the chief executive officer owned 8,941,533 shares in the company, valued at $586,206,903.48. This trade represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Erik Phelps sold 9,464 shares of Tempus AI stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.43, for a total value of $562,445.52. Following the completion of the sale, the executive vice president directly owned 79,816 shares in the company, valued at $4,743,464.88. This represents a 10.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 596,035 shares of company stock worth $37,505,125 in the last three months. 26.27% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC grew its stake in shares of Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after buying an additional 381,816 shares during the period. State Street Corp lifted its holdings in Tempus AI by 9.8% in the fourth quarter. State Street Corp now owns 1,616,338 shares of the company’s stock valued at $95,445,000 after acquiring an additional 143,676 shares during the last quarter. Voloridge Investment Management LLC grew its position in Tempus AI by 183.0% in the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after acquiring an additional 1,039,176 shares during the period. Franklin Resources Inc. increased its stake in Tempus AI by 0.4% during the third quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company’s stock worth $117,523,000 after acquiring an additional 5,375 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in Tempus AI by 6.4% in the third quarter. AQR Capital Management LLC now owns 904,872 shares of the company’s stock valued at $73,032,000 after purchasing an additional 54,692 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on TEM shares. Canaccord Genuity Group dropped their price objective on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, December 22nd. BTIG Research increased their price target on shares of Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. JPMorgan Chase & Co. cut their price objective on shares of Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Piper Sandler lowered their target price on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th. Finally, HC Wainwright dropped their target price on Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Eight research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Tempus AI currently has an average rating of “Hold” and an average target price of $85.92.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Launched HRD‑RNA and added lung‑cancer screening via a Median Technologies partnership — broadens Tempus’s clinical offerings for treatment selection and early detection, supporting future revenue diversification and cross‑sell into oncology workflows. Tempus AI Expands Cancer Workflow With HRD-RNA Launch And Lung Screening
• Positive Sentiment: Imaging push gains traction — analysts note the Median deal and prior FDA clearances strengthen Tempus’s move into radiology/AI imaging, which could increase Pixel platform adoption and create new revenue streams. Here’s How Tempus AI Is Tapping the Imagining Space
• Neutral Sentiment: Earnings preview — analysts and previews flag key items investors will watch in the print: revenue growth, margin progress, guidance, and product monetization (testing, Pixel imaging uptake). The report sets expectations that could drive post‑report volatility. What’s Next: Tempus AI’s Earnings Preview
• Neutral Sentiment: Live earnings coverage in play — real‑time updates and market reaction are being tracked; results or guidance surprises are the most likely immediate drivers of today’s price action. Live Earnings: Will Tempus AI Surprise Wall Street Tonight?
• Negative Sentiment: Significant insider selling reported — multiple senior executives (CEO, CFO, and EVPs) sold shares on 2/23, totaling roughly $2.9M of disclosed sales; large, clustered insider sales can raise investor concern about insider confidence or signal personal liquidity moves. Tempus AI (NASDAQ:TEM) CEO Sells $566,407.60 in Stock Tempus AI (NASDAQ:TEM) CFO Sells $595,460.20 in Stock Tempus AI (NASDAQ:TEM) EVP Sells $660,334.19 in Stock

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.